Skip to main content

Advertisement

SpringerLink
Log in

Eradication of minimal residual disease in chronic lymphocytic leukemia

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Although fludarabine-based regimens and monoclonal antibodies are able to induce high overall and complete remission rates in patients with chronic lymphocytic leukemia (CLL), a major impact on overall survival or even potential cure by these treatments is still lacking. Increased sensitivity and specificity of flow cytometry and polymerase chain reaction techniques enable us to detect few CLL cells in peripheral blood and bone morrow. This has brought significant advancement into the evaluation of response quality of CLL treatment. The eradication of minimal residual disease (MRD) below measurable levels seems to be critical to overcome recurring clonal expansion resulting in disease progression or relapse. Several studies suggest that achieving MRD negativity in patients with CLL provokes prolonged response duration and survival. Thus, elimination of MRD should become a surrogate end point of modern clinical trials and a goal in CLL. This review summarizes the current status of and future strategies for MRD eradication in CLL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Binet JL, Lepoprier M, Dighiero G, et al.: A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977, 40:855-864.

    Google Scholar 

  2. Dighiero G, Binet J-L: When and how to treat chronic lymphocytic leukemia. N Engl J Med 2000, 343:1799–1801.

    Article  PubMed  CAS  Google Scholar 

  3. Rai KR, Sawitsky A, Cronkite EP, et al.: Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46:219–234.

    PubMed  CAS  Google Scholar 

  4. Crespo M, Bosch F, Villamor N, et al.: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348:1764–1775.

    Article  PubMed  CAS  Google Scholar 

  5. Dohner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910–1916.

    Article  PubMed  CAS  Google Scholar 

  6. Hamblin TJ, Davis Z, Gardiner A, et al.: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848–1854.

    PubMed  CAS  Google Scholar 

  7. Rawstron AC, Villamor N, Ritgen M, et al.: International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007, 21:956–964.

    PubMed  CAS  Google Scholar 

  8. Bottcher S, Ritgen M, Pott C, et al.: Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004, 18:1637–1645.

    Article  PubMed  CAS  Google Scholar 

  9. Moreno C, Villamor N, Colomer D, et al.: Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006, 107:4563–4569.

    Article  PubMed  CAS  Google Scholar 

  10. Rawstron AC, Kennedy B, Evans PA, et al.: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001, 98:29–35.

    Article  PubMed  CAS  Google Scholar 

  11. Catovsky D, Richards S, Matutes E, et al.: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007, 370:230–239.

    Article  PubMed  CAS  Google Scholar 

  12. Eichhorst BF, Busch R, Hop finger G, et al.: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107:885–891.

    Article  PubMed  CAS  Google Scholar 

  13. Rai KR, Peterson BL, Appelbaum FR, et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750–1757.

    Article  PubMed  CAS  Google Scholar 

  14. Brugiatelli M, Bandini G, Barosi G, et al.: Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2006, 91:1662–1673.

    PubMed  Google Scholar 

  15. Robertson LE, Huh YO, Butler JJ, et al.: Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992, 80:29–36.

    PubMed  CAS  Google Scholar 

  16. Maloum K, Charlotte F, Divine M, et al.: A comparison of the sensitivity of flow cytometry and bone marrow biopsy in the detection of minimal residual disease in chronic lymphocytic leukemia. Haematologica 2006, 91:860–861.

    PubMed  Google Scholar 

  17. Cazin B, Maloum K, Creteil M, et al.: Oral fludarabine phosphate and cyclophosphamide in previously untreated CLL: final response and follow-up in 75 patients [abstract 1598]. Presented at the 45th annual meeting of the American Society of Hematology. San Diego; December 6–9, 2003.

  18. Bosch F, Ferrer A, Lopez-Guillermo A, et al.: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002, 119:976–984.

    Article  PubMed  CAS  Google Scholar 

  19. Bosch F, Ferrer A, Villamor N, et al.: Combination chemotherapy with fludarabine, cyclophosphamide and mitoxantrone (FCM) induces a high response rate in previously untreated CLL [abstract 718]. Presented at the 47th annual meeting of the American Society of Hematology. Atlanta; December 10–13, 2005.

  20. Keating MJ, O’Brien S, Albitar M, et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4079–4088.

    Article  PubMed  CAS  Google Scholar 

  21. Tam CS, Wolf M, Prince HM, et al.: Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006, 106:2412–2420.

    Article  PubMed  CAS  Google Scholar 

  22. Keating MJ, O’Brien S, Albitar M, et al.: Extended follow-up of a chemo-immunotherapy regimen FCR (fludarabine, F; cyclophosphamide, C; and rituximab, R) as initial therapy for chronic lymphocytic leukemia (CLL) [abstract 2118]. Presented at the 47th annual meeting of the American Society of Hematology. Atlanta; December 10–13, 2005.

  23. Wierda W, O’Brien S, Wen S, et al.: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4070–4078.

    Article  PubMed  CAS  Google Scholar 

  24. Faderl S, Wierda WG, O’Brien S, et al.: Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) as frontline therapy for CLL: results of a phase 2 study [abstract 2836]. Presented at the 48th annual meeting of the American Society of Hematology. Orlando; December 9–12, 2006.

  25. Lozanski G, Heerema NA, Flinn IW, et al.: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004, 103:3278–3281.

    Article  PubMed  CAS  Google Scholar 

  26. Moreton P, Kennedy B, Lucas G, et al.: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005, 23:2971–2979.

    Article  PubMed  CAS  Google Scholar 

  27. Osuji NC, Del Giudice I, Matutes E, et al.: The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005, 90:1435–1436.

    PubMed  CAS  Google Scholar 

  28. Stilgenbauer S, Winkler D, Krober A, et al.: Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL: interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG) [abstract 478]. Presented at the 46th annual meeting of the American Society of Hematology. San Diego; December 4–7, 2004.

  29. Keating MJ, Flinn I, Jain V, et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554–3561.

    Article  PubMed  CAS  Google Scholar 

  30. Lundin J, Kimby E, Bjorkholm M, et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100:768–773.

    Article  PubMed  CAS  Google Scholar 

  31. Osterborg A, Dyer MJ, Bunjes D, et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997, 15:1567–1574.

    PubMed  CAS  Google Scholar 

  32. Osterborg A, Fassas AS, Anagnostopoulos A, et al.: Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996, 93:151–153.

    Article  PubMed  CAS  Google Scholar 

  33. Hale G, Rebello P, Brettman LR, et al.: Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004, 104:948–955.

    Article  PubMed  CAS  Google Scholar 

  34. Mayer J, Robak T, Skotnicki A, et al.: Impact of prognostic factors on outcome in a phase III study comparing alemtuzumab to chlorambucil as first-line therapy for Bcell chronic lymphocytic leukemia (BCLL) [abstract 7035]. Presented at the 43th annual meeting of the American Society of Clinical Oncology. Chicago; June 1–5, 2007.

  35. Hillmen P, Skotnicki A, Robak T, et al.: Alemtuzumab (Campath(R), MabCampath(R)) has superior progression free survival (PFS) vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [abstract 301]. Presented at the 48th annual meeting of the American Society of Hematology. Orlando; December 9–12, 2006.

  36. Elter T, Borchmann P, Schulz H, et al.: Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005, 23:7024–7031.

    Article  PubMed  CAS  Google Scholar 

  37. Tedeschi A, Montillo M, Miqueleiz S, et al.: Combination of fludarabine (FAMP), cyclophosphamide (CTX) and alemtuzumab for patients with relapsed chronic lymphocytic leukemia (CLL) [abstract 5036]. Presented at the 47th annual meeting of the American Society of Hematology. Atlanta; December 10–13, 2005.

  38. Smolewski P, Szmigielska-Kaplon A, Cebula B, et al.: Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma 2005, 46:87–100.

    Article  PubMed  CAS  Google Scholar 

  39. Wierda WG, O’Brien S, Faderl S, et al.: Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL [abstract 31]. Presented at the 48th annual meeting of the American Society of Hematology. Orlando; December 9–12, 2006.

  40. Dyer MJ, Kelsey SM, Mackay HJ, et al.: In vivo ‘purging’ of residual disease in CLL with Campath-1H. Br J Haematol 1997, 97:669–672.

    Article  PubMed  CAS  Google Scholar 

  41. O’Brien SM, Kantarjian HM, Thomas DA, et al.: Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003, 98:2657–2663.

    Article  PubMed  CAS  Google Scholar 

  42. Wierda WG, Kipps TJ, Keating MJ, et al.: Self-administered, subcutaneous (SQ) alemtuzumab to eliminate residual disease in patients (pts) with CLL [abstract 2839]. Presented at the 48th annual meeting of the American Society of Hematology. Orlando; December 9–12, 2006.

  43. Montillo M, Tedeschi A, Miqueleiz S, et al.: Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006, 24:2337–2342.

    Article  PubMed  CAS  Google Scholar 

  44. Wendtner CM, Ritgen M, Schweighofer CD, et al.: Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission—experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004, 18:1093–1101.

    Article  PubMed  CAS  Google Scholar 

  45. Ritgen M, Schweighofer C, Fingerle-Rowson G, et al.: Consolidation with alemtuzumab in first remission induces pronounced MRD reduction and clinical remissions-update on a randomized phase III trial of the German CLL Study Group (GCLLSG) [abstract 2506]. Presented at the 46th annual meeting of the American Society of Hematology. San Diego; December 4–7, 2004.

  46. Schweighofer C, Ritgen M, Eichhorst B, et al.: Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia (CLL) in first remission-long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG) [abstract 33]. Presented at the 48th annual meeting of the American Society of Hematology. Orlando; December 9–12, 2006.

  47. Karlsson C, Norin S, Kimby E, et al.: Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia 2006, 20:2204–2207.

    Article  PubMed  CAS  Google Scholar 

  48. Dreger P, Corradini P, Kimby E, et al.: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007, 21:12–17.

    Article  PubMed  CAS  Google Scholar 

  49. Dreger P: Transplantation strategies in chronic lymphocytic leukemia: current concepts of the German CLL Study Group and the EBMT. Ann Hematol 2004, 83(Suppl 1):S68–S70.

    PubMed  Google Scholar 

  50. Gribben JG, Zahrieh D, Stephans K, et al.: Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005, 106:4389–4396.

    Article  PubMed  CAS  Google Scholar 

  51. Milligan DW, Kochethu G, Dearden C, et al.: High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia. Br J Haematol 2006, 133:173–175.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, University of Cologne, Kerpener Strasse 62, D-50937, Köln, Germany

    Carmen Diana Schweighofer

Authors
  1. Carmen Diana Schweighofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Hallek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clemens-Martin Wendtner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carmen Diana Schweighofer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schweighofer, C.D., Hallek, M. & Wendtner, CM. Eradication of minimal residual disease in chronic lymphocytic leukemia. Curr Hematol Malig Rep 3, 54–60 (2008). https://doi.org/10.1007/s11899-008-0009-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-008-0009-7

Keywords

Search

Navigation